Literature DB >> 14976209

Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia.

Ian Pitha-Rowe1, Bret A Hassel, Ethan Dmitrovsky.   

Abstract

Acute promyelocytic leukemia (APL) cases expressing the t(15,17) product, promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha), have clinical remissions through leukemic cell differentiation after all-trans-retinoic acid (RA) treatment. This differentiation therapy propelled interest in uncovering molecular mechanisms for RA-dependent APL differentiation. We previously identified the ubiquitin-activating enzyme-E1-like protein (UBE1L) as an RA-regulated target gene in APL that triggers PML/RARalpha degradation and apoptosis. This study reports that conjugation of the ubiquitin-like species, interferon-stimulated gene, 15-kDa protein (ISG15), also occurs during RA-induced APL differentiation. Knock-down of UBE1L expression inhibited this conjugation. RA treatment of APL and other RA-responsive leukemic cells induced expression of UBE1L and ISG15 as well as intracellular ISG15 conjugates. Notably, ISG15 conjugation did not occur in RA-resistant NB4-R1 APL cells. Induction of UBE1L and ISG15 along with ISG15 conjugation in RA-sensitive NB4-S1 APL cells were detected following treatment with specific retinoids and type I interferon (IFN). UBE1L and ISG15 mRNAs were co-expressed in normal human tissues that were examined. In contrast, UBE1L mRNA expression was markedly repressed in several cancer cell lines. A physical association was found between UBE1L and ISG15 in vivo. This required the conserved diglycine motif in the carboxyl terminus of ISG15. Targeting UBE1L expression with small inhibitory RNA or small hairpin RNA inhibited IFN and RA-induced ISG15 conjugation. Formation of ISG15 conjugates through induction of an activating enzyme represents a novel pharmacologic mechanism for regulation of this ubiquitin-related species. Taken together, the observed rela tionship between expression of UBE1L and ISG15, their physical association and coordinate regulation, and induced ISG15 conjugation during leukemic cell differentiation implicate an important role for these proteins in retinoid response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976209     DOI: 10.1074/jbc.M309259200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Authors:  Atsushi Okumura; Gengshi Lu; Ian Pitha-Rowe; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-24       Impact factor: 11.205

Review 2.  Viral defense, carcinogenesis and ISG15: novel roles for an old ISG.

Authors:  Ian F Pitha-Rowe; Paula M Pitha
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-03       Impact factor: 7.638

3.  Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

4.  Isg15 controls p53 stability and functions.

Authors:  Yi-Fu Huang; Sheena Wee; Jayantha Gunaratne; David P Lane; Dmitry V Bulavin
Journal:  Cell Cycle       Date:  2014-05-20       Impact factor: 4.534

5.  Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15.

Authors:  Young Joo Jeon; Mi Gyeong Jo; Hee Min Yoo; Se-Hoon Hong; Jung-Mi Park; Seung Hyeun Ka; Kyu Hee Oh; Jae Hong Seol; Yong Keun Jung; Chin Ha Chung
Journal:  J Clin Invest       Date:  2012-06-18       Impact factor: 14.808

6.  Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.

Authors:  Mohammad Salajegheh; Sek Won Kong; Jack L Pinkus; Ronan J Walsh; Anne Liao; Remedios Nazareno; Anthony A Amato; Bryan Krastins; Chris Morehouse; Brandon W Higgs; Bahija Jallal; Yihong Yao; David A Sarracino; Kenneth C Parker; Steven A Greenberg
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

7.  UBE1L causes lung cancer growth suppression by targeting cyclin D1.

Authors:  Qing Feng; David Sekula; Yongli Guo; Xi Liu; Candice C Black; Fabrizio Galimberti; Sumit J Shah; Lorenzo F Sempere; Vincent Memoli; Jesper B Andersen; Bret A Hassel; Konstantin Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice.

Authors:  Xiaoyan Yin; Xiuli Cong; Ming Yan; Dong-Er Zhang
Journal:  Lung Cancer       Date:  2008-06-24       Impact factor: 5.705

9.  UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.

Authors:  Sumit J Shah; Steven Blumen; Ian Pitha-Rowe; Sutisak Kitareewan; Sarah J Freemantle; Qing Feng; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

10.  Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.

Authors:  Shanhu Hu; Yun Lu; Bernardo Orr; Kristina Godek; Lisa Maria Mustachio; Masanori Kawakami; David Sekula; Duane A Compton; Sarah Freemantle; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2015-08-24       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.